Biological pathway involvement in melanoma
heterogeneity and drug-induced resistance
Sarah

1
Pack ,

Yapeng

1,2
Su ,

James R.

1,2
Heath

1Institute

for Systems Biology, Seattle, WA
2NanoSystems Biology Cancer Center, California Institute of Technology, Pasadena, CA

Motivation and Objectives

Results: Pathway Analysis of Day 24 Melanoma Cells

Tumors develop resistance to numerous drug therapies, and this remains a major obstacle in treating
many types of non-surgical cancers. Melanoma provides a good model system for studying drug
resistance in cancer due to its high propensity to incur resistance after a significant initial response to
a drug. Genes that are highly expressed in melanoma cancer cells have been studied, but in order to
further understand the collective function of these highly expressed genes we must analyze gene
sets, or pathways. A single gene’s function is rarely independent of other genes, and pathway analysis
takes this into account.
Our objective is to simplify single-cell RNA sequence data to model pathways and pinpoint which
unique pathways are up-regulated and down-regulated in drug resistant and nonresistant melanoma
cell phenotypes. Identifying these important pathways provides a more accurate depiction of
melanoma heterogeneity and informs us of the pathways that are likely to be effective targets for
new drug therapies, bringing us closer to overcoming drug-induced resistance.
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Melanoma Cell Subpopulation Locations:

Background Discussion

Cytoscape Model: Differentially Expressed
Pathways between Resistant and Nonresistant
Melanoma Cell Clusters

More than half of melanoma patients have a driver mutation in the BRAF
protein, and an inhibitor that targets the mutated BRAF protein leads to
significant initial response in these patients. Despite this initial response,
the tumors always come back, indicating that tumor cells have also
developed resistance to the BRAF inhibitor.
During BRAF inhibitor treatment,
melanoma cells will transition from
the original melanocytic, drug
sensitive cancer cell phenotype
towards a stem-like drug-resistant
cancer cell phenotype. This process
is called Melanocyte to Neural-crest
Transition (MNT), and this process
causes non-genetic resistance to the
BRAF inhibitor drug.
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Future Direction

Results: Pathway Analysis of Time Series Data
• Model the emergence of heterogeneity over time in important pathways.
• How does gene expression change over time with exposure to BRAFi in these pathways?
Emergence of Melanoma Heterogeneity through Time:
Expression of Marker Genes:

Surprisal Analysis:
• We are planning to use surprisal analysis, a method derived from physical chemistry, to cluster our
cells and find new modules of coregulated genes that differentiate our novel cluster from the
other resistant and nonresistant subpopulations.
• We will use Cytoscape to visually represent pathways of interest
• We will first use our day 24 melanoma cells and then extend our analysis to our time series data.

Melanoma Subpopulations: day 24
Melanoma cells are not homogeneous, and we found
four unique subpopulations in our day 24 melanoma
cells (shown on the plot at right). Three of the four
clusters are known phenotypes of melanoma cells: drugsensitive melanocytic cells, drug tolerant neural-crest
cells, and drug-resistant mesenchymal cells. Researchers
also found a novel resistant cluster of cells, seen in blue
on the plot at right. Identifying the important pathways
in both resistant clusters, especially the previously
unknown novel cluster increases our understanding of
cell-state transitions.

Methods
Research Question:
• What do the patterns of pathway expression for known resistant
subpopulations of melanoma cells tell us about the cell-state transitions that
lead to drug-induced resistance?
Approach:
• Identify unique pathways for each subpopulation using Gene Set Expression
Analysis (GSEA) and calculate the levels of pathway expression (upregulation
or downregulation) for each cell using Gene Set Variation Analysis (GSVA).
• Visually represent pathway relationships using Cytoscape, an open source
software platform for visualizing molecular interaction networks and
biological pathways.
• Visually represent how pathway expression changes over time after exposure
to a BRAF inhibitor drug with trajectory analysis of single-cell RNA sequence
data combined with pathway scores obtained from GSVA analysis.

•

Transpose pathway score data calculated from GSVA onto single-cell RNA sequence
trajectory plot. Known patterns of pathway upregulation and downregulation are shown.
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